Kengreal
(Cangrelor)ApprovedSmall molecule
Chiesi Farmaceutici S.p.A.Cangrelor is used to prevent blood clots in patients undergoing heart catheterization procedures, particularly in those at high risk for clot formation during the procedure.[2] Kengreal is currently approved and in use across 11 indications[4].[1]
Kengreal is one of 246 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
11
Indications
28
Total Trials
4
Active Trials
245
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
7
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1Kengreal
Chiesi Farmaceutici S.p.A.Approved
Activase
RochePreclinical
Folvite
Eli LillyPreclinical
Zometa
PfizerPreclinical
Repatha
AmgenPreclinical
Proamatine
TakedaPreclinical
Pradaxa
Boehringer IngelheimPreclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Zantac 150
CChattem
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Platelet Inhibition3 trials
Percutaneous Coronary Intervention3 trials
Myocardial Infarction2 trials
GIST2 trials
15 more indications
Acute Myocardial Infarction1 trial
ESS1 trial
Stroke1 trial
Itching1 trial
Treatment1 trial
Randomized1 trial
Unspecified2 trials
Regulatory
FDA Approval Timeline[5]
Jun 22, 2015
KENGREAL
NDA NDA204958
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Kengreal drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Cangrelor. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Purinergic Receptor P2Y12 Antagonist; Purinergic Receptor P2Y12 Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company